Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Savient Pharmaceuticals, Inc., et al.,
Case Number:
1:13-bk-12680
Court:
Nature of Suit:
Firms
- Ashby & Geddes
- ASK LLP
- Buchalter APC
- Cole Schotz
- Dilworth Paxson
- Faegre Drinker
- Fox Rothschild
- Frost Brown
- Gellert Scali
- GrayRobinson
- Hunton Andrews
- Kirkland & Ellis
- Klehr Harrison
- Landis Rath
- Maslon LLP
- McCarter & English
- Norton Rose
- Pachulski Stang
- Paul Weiss
- Richards Layton
- Robinson & Cole
- Skadden Arps
- Stroock & Stroock
- White and Williams
- Young Conaway
Companies
- Crealta Pharmaceuticals LLC
- Epiq Systems Inc.
- Fujifilm
- Iron Mountain Inc.
- Lazard Ltd.
- Level 3 Communications Inc.
- McKesson Corp.
- Mesirow Financial Holdings Inc.
- Microsoft Corp.
- Savient Pharmaceuticals Inc.
- The PNC Financial Services Group Inc.
- U.S. Bancorp
- Wolters Kluwer
Government Agencies
Sectors & Industries:
-
May 19, 2014
Bankrupt Savient Wins Approval For Ch. 11 Plan
A Delaware bankruptcy judge on Monday blessed Savient Pharmaceuticals Inc.'s Chapter 11 liquidation plan, allowing the estate of the former drug developer to distribute $120 million in sale proceeds and other remaining assets among its creditors.
-
May 05, 2014
IRS Says Savient's Ch. 11 Plan Is Missing Tax Payments
Savient Pharmaceuticals Inc.'s Chapter 11 liquidation does not cover taxes owed to the federal government, the Internal Revenue Service argued on Monday.
-
March 17, 2014
Savient Gets Nod For Ch. 11 Disclosure Statement
A Delaware bankruptcy judge on Monday approved Savient Pharmaceuticals Inc.'s Chapter 11 disclosure statement, allowing the drug developer to solicit votes for a liquidation plan that would see creditors divvy up proceeds from its $120 million sale.
-
February 10, 2014
Savient Pharma Unveils Ch. 11 Plan
Drug developer Savient Pharmaceuticals Inc. unveiled its Chapter 11 plans in Delaware bankruptcy court Monday, calling for the liquidation of its U.S. and international assets that were not picked up by Crealta Pharmaceuticals LLC at auction.
-
December 13, 2013
Bankrupt Savient Gets OK For $120M Sale To Crealta
A Delaware bankruptcy judge on Friday blessed drug developer Savient Pharmaceuticals Inc.'s sale to Crealta Pharmaceuticals LLC for $120.4 million, more than twice the price initially established by the debtor's stalking horse bidder.
-
December 11, 2013
Bankrupt Savient Takes $120M Bid From Pharma Co. Crealta
Drug developer Savient Pharmaceuticals Inc. announced Tuesday it will sell the bulk of its assets to Crealta Pharmaceuticals LLC, which submitted a $120.4 million offer at the company's bankruptcy auction.
-
November 25, 2013
Savient's Unsecured Creditors Blast Cash-Collateral Motion
Unsecured creditors blasted Savient Pharmaceuticals Inc.'s plan to fund its stay in Chapter 11, saying its proposed cash-collateral motion provides secured bondholders with large and unnecessary payments but brings the drugmaker little in return.